Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis
- 14 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Familial Cancer
- Vol. 19 (3), 223-239
- https://doi.org/10.1007/s10689-020-00170-9
Abstract
Multigene panel tests for hereditary cancer syndromes are increasingly utilized in the care of colorectal cancer (CRC) and polyposis patients. However, widespread availability of panels raises a number of questions including which patients should undergo testing, which genes should be included on panels, and the settings in which panels should be ordered and interpreted. To address this knowledge gap, key questions regarding the major issues encountered in clinical evaluation of hereditary CRC and polyposis were designed by the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position Statement Committee and leadership. A literature search was conducted to address these questions. Recommendations were based on the best available evidence and expert opinion. This position statement addresses which genes should be included on a multigene panel for a patient with a suspected hereditary CRC or polyposis syndrome, proposes updated genetic testing criteria, discusses testing approaches for patients with mismatch repair proficient or deficient CRC, and outlines the essential elements for ordering and disclosing multigene panel test results. We acknowledge that critical gaps in access, insurance coverage, resources, and education remain barriers to high-quality, equitable care for individuals and their families at increased risk of hereditary CRC.Keywords
This publication has 100 references indexed in Scilit:
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences of the United States of America, 2011
- Frequent Gastrointestinal Polyps and Colorectal Adenocarcinomas in a Prospective Series of PTEN Mutation CarriersGastroenterology, 2010
- Inactivating germ-line and somatic mutations in polypeptide N -acetylgalactosaminyltransferase 12 in human colon cancersProceedings of the National Academy of Sciences of the United States of America, 2009
- EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndromeGenetics in Medicine, 2009
- Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?Genetics in Medicine, 2009
- Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal CancerJournal of Clinical Oncology, 2008
- Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patientsJournal of Medical Genetics, 2008
- Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutationsJournal of Medical Genetics, 2007
- Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)The New England Journal of Medicine, 2005
- Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriersHuman Genetics, 2002